API | motavizumab

motavizumab Report issue

Biologics mAb Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Motavizumab is a humanized monoclonal antibody. It is being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
motavizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Fusion glycoprotein F0 (Human respiratory syncytial virus) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

medi-524 | motavizumab | numax

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Healthy Volunteers (Phase 3)

Heart Defects, Congenital (Phase 2)

Infant, Premature (Phase 2)

Lung Diseases (Phase 2)

Respiratory Sounds (Phase 3)

Respiratory Syncytial Virus Infections (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue